Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H31NO10 |
| Molecular Weight | 541.5464 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@@H]1C[C@](C)(O)CC2=CC3=C(C(=O)C4=C(C3=O)C5=C(C=C4O)[C@@]6(C)O[C@@H](O5)[C@@H](O)[C@@H]([C@H]6O)N(C)C)C(O)=C12
InChI
InChIKey=LWYJUZBXGAFFLP-AOZXJLOUSA-N
InChI=1S/C28H31NO10/c1-27(36)8-10-6-11-16(21(32)15(10)14(9-27)37-5)22(33)17-13(30)7-12-24(18(17)20(11)31)38-26-23(34)19(29(3)4)25(35)28(12,2)39-26/h6-7,14,19,23,25-26,30,32,34-36H,8-9H2,1-5H3/t14-,19+,23+,25-,26?,27-,28-/m1/s1
| Molecular Formula | C28H31NO10 |
| Molecular Weight | 541.5464 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Menogaril is a semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin. Biochemical studies indicated that, in comparison to doxorubicin, menogaril is bound weakly to DNA, inhibits RNA synthesis less, and has different cell cycle phase-specific cytotoxicity. Menogaril acts as a cleavable complex-stabilizing topoisomerase II inhibitor. Menogaril has been studied in the treatment of various cancers.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885. | 2001-04 |
|
| Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia. | 2000-08 |
|
| Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar. | 1997-10-28 |
|
| Menogaril, an anthracycline derivative, inhibits DNA topoisomerase II by stabilizing cleavable complexes. | 1992-09 |
|
| Menogaril: a new anthracycline agent entering clinical trials. | 1984 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10638487
Phase II trial of menogaril in non-Hodgkin's lymphomas. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:53:51 GMT 2025
by
admin
on
Wed Apr 02 07:53:51 GMT 2025
|
| Record UNII |
8JSV4O30HQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1594
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MENOGARIL
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
DTXSID601024504
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
100000081494
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
C1389
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
5230
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
71628-96-1
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
m813
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | Merck Index | ||
|
D017290
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
8JSV4O30HQ
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
T-22
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
269148
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
SUB08742MIG
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL1234391
Created by
admin on Wed Apr 02 07:53:51 GMT 2025 , Edited by admin on Wed Apr 02 07:53:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |